Yusuf Emre Erdi

Yusuf Emre Erdi

Auto-generated profile, based on publicly available information

Yusuf Emre Erdi

Department of Medical Physics, Memorial Sloan-Kettering Cancer Center, New York, NY

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 July 2005 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
HSHeiko Schöder
Heiko Schöder
ANAriela Noy
Ariela Noy
MGMithat Gönen
Mithat Gönen
LWLijun Weng
Lijun Weng
DGDavid Green
David Green
HYHenry W.D. Yeung
Henry W.D. Yeung
Purpose: 18Fluorodeoxyglucose positron emission tomography (FDG PET) is widely used for the staging of lymphoma. We investigated whether the intensity of tumor FDG uptake could differentiate between indolent and aggressive disease.Materials and Methods: PET studies of 97 patients with non-Hodgkin's lymphoma who were untreated or had relapsed and/or persistent disease and had not received treatment within the last 6 months were analyzed, and the highest standardized uptake value (SUV) per study was recorded. Correlations were made with histopathology.Results: FDG uptake was lower in indolent than in aggressive lymphoma for patients with new (SUV, 7.0 ± 3.1 v 19.6 ± 9.3; P < .01) and relapsed (SUV, 6.3 ± 2.7 v 18.1 ± 10.9; P = .04) disease. Despite overlap between indolent and aggressive disease in the low SUV range (indolent, 2.3 to 13.0; aggressive, 3.2 to 43.0), all cases of indolent lymphoma had an SUV ≤ 13. A receiver operating characteristic (ROC) analysis demonstrated that the SUV distinguished reasonably well between aggressive and indolent disease (area under ROC curve, 84.7%), and an SUV > 10 excluded indolent lymphoma with a specificity of 81%. With a higher cutoff for the SUV, the specificity would have been higher.Conclusion: FDG uptake is lower in indolent than in aggressive lymphoma. Patients with NHL and SUV > 10 have a high likelihood for aggressive disease. This information may be helpful if there is discordance between biopsy and clinical behavior.

8 November 2004 in Medical Physics
Verified
Journal Article
Closed access
PDF file
SNS. A. Nehmeh
S. A. Nehmeh
YEY. E. Erdi
Y. E. Erdi
TPT. Pan
T. Pan
APA. Pevsner
A. Pevsner
KRK. E. Rosenzweig
K. E. Rosenzweig
JHJ. L. Humm
J. L. Humm

1 January 2002 in Radiotherapy and Oncology
Verified
Journal Article
Closed access
YEYusuf E Erdi
Yusuf E Erdi
KRKenneth Rosenzweig
Kenneth Rosenzweig
AEAlev K Erdi
Alev K Erdi
HMHomer A Macapinlac
Homer A Macapinlac
YHYu-chi Hu
Yu-chi Hu
EYEllen D Yorke
Ellen D Yorke

1 May 2008 in Seminars in Nuclear Medicine
Verified
Journal Article
Closed access
SNSadek A. Nehmeh
Sadek A. Nehmeh
YEYusuf E. Erdi
Yusuf E. Erdi

21 February 2002 in Medical Physics
Verified
Journal Article
Closed access
PDF file
SNS. A. Nehmeh
S. A. Nehmeh
YEY. E. Erdi
Y. E. Erdi
CLC. C. Ling
C. C. Ling
KRK. E. Rosenzweig
K. E. Rosenzweig
OSO. D. Squire
O. D. Squire
JHJ. L. Humm
J. L. Humm

12 May 2004 in Medical Physics
Verified
Journal Article
Closed access
PDF file
SNS. A. Nehmeh
S. A. Nehmeh
YEY. E. Erdi
Y. E. Erdi
TPT. Pan
T. Pan
EYE. Yorke
E. Yorke
GMG. S. Mageras
G. S. Mageras
JHJ. L. Humm
J. L. Humm